Genitourinary Cancers

Atezolizumab shows similar efficacy in upper tract urothelial carcinoma and standard bladder cancer

June 19, 2020

Median overall survival is the same for both malignancies, study results show.

Prostate Ca assay appears similarly predictive of adverse pathology in African American, Caucasian patients

June 15, 2020

In this video, Eric Klein, MD, discusses a study evaluating the 17-gene Oncotype DX Genomic Prostate Score assay in African American and Caucasian American men.

Research confirms prognostic performance of genomic classifier

June 10, 2020

The classifier can be a useful adjunct for clinical decision-making, an investigator says.

Is a reduced bacillus Calmette-Guérin regimen feasible?

June 02, 2020

"In the era of BCG shortage, it would have been highly desirable to demonstrate the efficacy and safety of fewer BCG instillations for high-risk bladder cancer. However, reduced frequency of maintenance BCG instillations is associated with increased risk of cancer recurrence, albeit with fewer adverse effects," writes Badar M. Mian, MD.

Robotics in GU oncology: Current status, future directions

May 22, 2020

The breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.

Operationalizing immunotherapy in urologic practice

May 22, 2020

A team-based approach is key to safely and appropriately dispensing checkpoint inhibitors, according to Gautam Jayram, MD.

FDA approves 2 PARP inhibitors for certain men with prostate cancer

May 21, 2020

The FDA has approved 2 poly (ADP-ribose) polymerase (PARP) inhibitors for men with metastatic castration-resistant prostate cancer who have certain genetic mutations, marking the first approvals of this newer drug class in prostate cancer.

Management of UTUC using a kidney-sparing approach

May 21, 2020

Advances in endourology have made kidney-sparing treatments a viable treatment option.

Dr. Angela Smith discusses the recent FDA approval of Jelmyto for low-grade UTUC

May 20, 2020

The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Angela B. Smith, MD, MS, regarding the significance of this approval for providers and patients.

Further Evaluation of Tivozanib Shows Promise for Relapsed, Refractory Renal Cell Carcinoma

May 19, 2020

Results from the phase III TIVO-3 trial of tivozanib (Fotivda) demonstrated a statistically significant improvement in median progression-free survival compared with sorafenib (Sutent), as well as favorable tolerability, in patients with relapsed or refractory renal cell carcinoma.